A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma Nasal Type

  • End date
    Jun 30, 2026
  • participants needed
  • sponsor
    ImmuneOncia Therapeutics Inc.
Updated on 26 January 2021
renal function


This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type


IMC-001 is a PD-L1 targeting, fully human monoclonal antibody. The purpose of this study is to determine and evaluate the efficacy and safety of IMC-001. 20mg/kg every 2 weeks, IV infusion of IMC-001 will be tested in subjects with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type.

Condition Angiocentric T-cell lymphoma, T-Cell Lymphoma, extranodal nk/t-cell lymphoma
Treatment IMC-001
Clinical Study IdentifierNCT04414163
SponsorImmuneOncia Therapeutics Inc.
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

ENKTL diagnosis
Histologically confirmed diagnosed with extranodal NK/T-cell lymphoma, nasal type
At least 1 previous line of systemic therapy
Documented disease progression of last therapy
Adult age(as defined by respective country)
The nature of the study and voluntarily sign an ICF
ECOG 0 or1
Adequate hematologic function, hepatic function, and renal function

Exclusion Criteria

Previously treated with an anti-PD-L1 or anti-PD-1 antibody
Known presence of symptomatic CNS metastases
Prior allogeneic HSCT or solid organ transplantation
Any active autoimmune disease or a documented history of autoimmune disease
Apparent active or latent TB and known viral infection with hepatitis B virus or hepatitis C virus
Pregnant or lactating
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note